208 results on '"Hashine, Katsuyoshi"'
Search Results
2. Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer
3. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial
4. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data
5. Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN
6. Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study
7. Report of case series: Correlation between pathological and radiological evaluation and clinical course of three cases of metastatic renal cell carcinoma with cytoreductive nephrectomy after combined immuno‐oncology therapy.
8. Validation study on the 2 mm diameter cutoff in lymph node‐positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real‐world data analysis from a Japanese cohort.
9. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN
10. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
11. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study
12. Sequential immune-targeted surgical therapy resulted in disease-free survival in a case with advanced renal cell carcinoma
13. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
14. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
15. Correction to: The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study
16. Long-term outcomes of a multicenter prospective observational study of active surveillance for early-stage prostate cancer: The PRIAS-JAPAN study.
17. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
18. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study.
19. Radical prostatectomy trends between 2010 and 2020 in Ehime, Japan, identified using data from the Medical Investigation Cancer Network (MICAN) study.
20. A case of EBV-associated adrenal leiomyoma
21. Patient-reported outcomes after robot-assisted radical prostatectomy and institutional learning curve for functional outcomes.
22. Predictive factors for the effectiveness of novel androgen receptor axis‐targeted agents in patients with metastatic prostate cancer.
23. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN
24. Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer
25. Influence of hospital surgical volume of radical prostatectomy on quality of perioperative care
26. Kinetics differences between PSA bounce and biochemical failure in patients treated with 125I prostate brachytherapy
27. MP69-19 EXTENDED ANALYSES OF PHASE II CLINICAL TRIAL OF SORAFENIB PLUS INTERFERON-ALPHA TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN JAPAN
28. A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
29. Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan
30. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma
31. Metastatic urachal adenocarcinoma successfully treated with surgery and chemotherapy
32. Health-related Quality of Life in the First Year after Laparoscopic Radical Prostatectomy Compared with Open Radical Prostatectomy
33. Final Results of a Phase II Study of S-1 in Patients with Cytokine-refractory Metastatic Renal Cell Carcinoma
34. Health-related quality of life and treatment outcomes for men with prostate cancer treated by combined external-beam radiotherapy and hormone therapy
35. Changes in perioperative management of radical prostatectomy using clinical pathways according to a standardized care plan: A multi-institutional study
36. MP01-03 CURRENT TREATMENT PATTERNS AND OUTCOMES OF 109 PATIENTS WITH SEX CORD STROMAL TUMORS IN JAPAN: A MULTI-INSTITUTIONAL STUDY.
37. Correlation between cancer location and oncological outcome after radical prostatectomy
38. Health-related quality of life after radical retropubic prostatectomy and permanent prostate brachytherapy: A 3-year follow-up study
39. Tertiary Gleason Pattern 5 and Oncological Outcomes after Radical Prostatectomy
40. Docetaxel–Prednisolone Combination Therapy for Japanese Patients with Hormone-refractory Prostate Cancer: a Single Institution Experience
41. Dietary Administration of Mushroom Mycelium Extracts in Patients with Early Stage Prostate Cancers Managed Expectantly: A Phase II Study
42. Health-related Quality of Life using SF-8 and EPIC Questionnaires after Treatment with Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy
43. Bladder Preservation Therapy Conducted by Intra-arterial Chemotherapy and Radiotherapy for Muscle Invasive Bladder Cancer
44. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
45. Radiation Pneumonitis Caused by a Migrated Brachytherapy Seed Lodged in the Lung
46. A Prospective Longitudinal Study Comparing a Radical Retropubic Prostatectomy and Permanent Prostate Brachytherapy Regarding the Health-related Quality of Life for Localized Prostate Cancer
47. Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer
48. Long-term Outcomes of 60 Gy Conventional Radiotherapy Combined with Androgen Deprivation for Localized or Locally Advanced Prostate Cancer
49. Predictor of Response to Salvage Radiotherapy in Patients with PSA Recurrence after Radical Prostatectomy: the Usefulness of PSA Doubling Time
50. Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.